Somed Cr Sp. z o.o. sp. k. Company Profile - Poland | Financials & Key Executives

Somed Cr Sp. z o.o. sp. k. (Poland)

Main Activities: General Medical and Surgical Hospitals

Secondary Activities: Research and Development in Biotechnology (except Nanobiotechnology) | Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) | All Other Miscellaneous Schools and Instruction | Ambulatory Health Care Services | Outpatient Care Centers

Full name: Somed Cr Sp. z o.o. sp. k.

Profile Updated: April 11, 2024

Somed Cr Sp. z o.o. sp. k. is a company based in Poland, with its head office in Warsaw. The company operates in the General Medical and Surgical Hospitals sector. The enterprise was incorporated on June 01, 2020. From the latest financial highlights, Somed Cr Sp. z o.o. sp. k. reported a net sales revenue increase of 26.38% in 2023. Over the same period, its total assets grew by 21.27%. The net profit margin of Somed Cr Sp. z o.o. sp. k. increased by 8.16% in 2023.

Headquarters
Ul. Adama Mickiewicza 25/36
Warsaw; Mazowieckie; Postal Code: 01-551

Contact Details: Purchase the Somed Cr Sp. z o.o. sp. k. report to view the information.

Basic Information

Outstanding Shares:

Purchase the Somed Cr Sp. z o.o. sp. k. report to view the information.

Incorporation Date:

June 01, 2020

Key Executives

Purchase this report to view the information.

Associate

Purchase this report to view the information.

Associate Partner

Purchase this report to view the information.

Limited Partner

Company Performance

Financial values in the chart are available after Somed Cr Sp. z o.o. sp. k. report is purchased.

Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service

Key Financial Highlights

Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.

Net sales revenue

26.38%▲

Total operating revenue

26.43%▲

Operating profit (EBIT)

81.33%▲

Net Profit (Loss) for the Period

71.01%▲

Total assets

21.27%▲

Total equity

69.25%▲

Operating Profit Margin (ROS)

10.8%▲

Net Profit Margin

8.16%▲

Return on Equity (ROE)

1.02%▲

Quick Ratio

1.16%▲

Cash Ratio

0.87%▲

Similar companies